Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
4.680
+0.230 (5.17%)
At close: Apr 2, 2025, 4:00 PM
4.900
+0.220 (4.70%)
After-hours: Apr 2, 2025, 6:14 PM EDT
Abeona Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
84
Market Cap
227.14M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ABEO News
- 1 day ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans - GlobeNewsWire
- 4 weeks ago - Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued - Seeking Alpha
- 4 months ago - Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 months ago - Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 5 months ago - Abeona Therapeutics® Announces Participation in November Investor Conferences - GlobeNewsWire